CIK 0001818794 · Large accelerated filer
Dyne Therapeutics, Inc.
Sign in to watch- Ticker
- DYN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 364883909
- Phone
- (781) 786-8230
- Business address
- 1560 TRAPELO ROAD, WALTHAM, MA, 02451
- Open-market buys, last 90 days
- $40,000
- in 1 filing
- Open-market sales, last 90 days
- $247,777
- in 3 filings, $248K under 10b5-1 plans
Net −$207,777. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-03-08 | McNeill Jonathan Chief Business Officer | Option exercise · Stock option (right to buy) 10b5-1 | −86,159 | 12,309 | ||
| 2024-03-08 | McNeill Jonathan Chief Business Officer | Option exercise · Stock option (right to buy) 10b5-1 | −3,841 | |||
| 2024-03-08 | Scalzo Richard William SVP, Head of Finance & Admin. | Option exercise 10b5-1 | +68,919 | $5.54 | $382K | 190,874 |
| 2024-03-08 | Scalzo Richard William SVP, Head of Finance & Admin. | Option exercise 10b5-1 | +17,333 | $5.54 | $96K | 208,207 |
| 2024-03-08 | Scalzo Richard William SVP, Head of Finance & Admin. | Sale 10b5-1 | −30,755 | $25.31 | $778K | 177,452 |
| 2024-03-08 | Scalzo Richard William SVP, Head of Finance & Admin. | Sale 10b5-1 | −55,208 | $26.72 | $1.5M | 122,244 |
| 2024-03-08 | Scalzo Richard William SVP, Head of Finance & Admin. | Sale 10b5-1 | −289 | $27.33 | $8K | 121,955 |
| 2024-03-08 | Scalzo Richard William SVP, Head of Finance & Admin. | Option exercise · Stock option (right to buy) 10b5-1 | −68,919 | 9,855 | ||
| 2024-03-08 | Scalzo Richard William SVP, Head of Finance & Admin. | Option exercise · Stock option (right to buy) 10b5-1 | −17,333 | 0 | ||
| 2024-03-08 | Brumm Joshua T CEO & President | Option exercise 10b5-1 | +153,931 | $5.54 | $853K | 708,316 |
| 2024-03-08 | Brumm Joshua T CEO & President | Option exercise 10b5-1 | +209,412 | $5.54 | $1.2M | 917,728 |
| 2024-03-08 | Brumm Joshua T CEO & President | Sale 10b5-1 | −202,238 | $25.30 | $5.1M | 715,490 |
| 2024-03-08 | Brumm Joshua T CEO & President | Sale 10b5-1 | −160,670 | $26.72 | $4.3M | 554,820 |
| 2024-03-08 | Brumm Joshua T CEO & President | Sale 10b5-1 | −435 | $27.38 | $12K | 554,385 |
| 2024-03-08 | Brumm Joshua T CEO & President | Option exercise · Stock option (right to buy) 10b5-1 | −153,931 | 0 | ||
| 2024-03-08 | Brumm Joshua T CEO & President | Option exercise · Stock option (right to buy) 10b5-1 | −209,412 | 133,269 | ||
| 2024-03-07 | Brumm Joshua T CEO & President | Sale 10b5-1 | −9,086 | $25.85 | $235K | 554,385 |
| 2024-03-07 | Beskrovnaya Oxana Chief Scientific Officer | Sale 10b5-1 | −2,373 | $25.85 | $61K | 154,433 |
| 2024-03-07 | HIGH SUSANNA GATTI Chief Operating Officer | Sale 10b5-1 | −1,591 | $25.85 | $41K | 186,291 |
| 2024-03-07 | Farwell Wildon Chief Medical Officer | Sale 10b5-1 | −8,364 | $25.80 | $216K | 154,732 |
Page 21 of 29 · 561 trades